<header id=042958>
Published Date: 2021-12-30 16:55:47 EST
Subject: PRO/AH/EDR> COVID-19 update (452): rapid test, omicron, Ab neutralization, school, WHO
Archive Number: 20211230.8700597
</header>
<body id=042958>
CORONAVIRUS DISEASE 2019 UPDATE (452): RAPID TEST, OMICRON, ANTIBODY NEUTRALIZATION, SCHOOL, WHO
************************************************************************************************
A ProMED-mail post
http://www.promedmail.org
ProMED-mail is a program of the
International Society for Infectious Diseases
http://www.isid.org

In this update:
[1] BinaxNow rapid test
[2] Omicron
[3] Antibody-mediated neutralization of omicron
[4] School
[5] WHO: Daily new cases reported (as of 29 Dec 2021)
[6] Global update: Worldometer accessed 29 Dec 2021 20:23 EST (GMT-5)

******
[1] BinaxNow rapid test
Date: Mon 27 Dec 2021
Source: medRxiv [edited]
https://www.medrxiv.org/content/10.1101/2021.12.22.21268219v1


ref [preprint]: Regan J, Flynn J, Choudhary M, et al. Detection of the omicron variant virus with the Abbott BinaxNow SARS-CoV-2 Rapid Antigen Assay. medRxiv 2021.12.22.21268219; doi: https://doi.org/10.1101/2021.12.22.21268219

Abstract
The US Centers for Disease Control and Prevention recommends rapid testing for SARS-CoV-2 infection as a key element of epidemic control. The Abbott BinaxNow is in widespread use in the United States for self-testing and as part of public health screening campaigns, but has not been evaluated for use with the omicron variant of SARS-CoV-2. We recruited individuals testing positive for COVID-19 PCR at an academic medical center. Anterior nasal swabs were stored in viral transport media and evaluated by viral load quantification and whole genome sequencing. We created serial dilutions from 2.5x103- 2.5x105 viral copies/specimen for 2 delta and omicron specimens, respectively, and tested each with the BinaxNow assay per manufacturer instructions. Results were interpreted by 3 readers, blinded to the specimen variant and concentration. All omicron and delta specimens with concentrations of 100 000 copies/swab or greater were positive by the BinaxNow Assay, a concentration similar to previously reported limits of detection for this assay. Assay sensitivity diminished below that. This study demonstrates that omicron variant SARS-CoV-2 infections are detected by the BinaxNow rapid antigen assay. Additional laboratory and clinical validation assessments are needed to better determine their limits of detection and performance in real-world settings.

--
communicated by:
Mary Marshall
<mjm2020@googlemail.com>

[Also note FDA just granted Emergency Use Authorization to Siemens Healthineers for its serial at-home Covid-19 test. https://www.fda.gov/media/155173/download - Mary Marshall]

******
[2] Omicron
Date: Wed 29 Dec 2021
Source: CIDRAP (Center for Infectious Disease Research and Policy) [edited]
https://www.cidrap.umn.edu/news-perspective/2021/12/omicron-activity-picks-pace-world-enters-pandemic-year-3


Omicron variant activity is surging across the country ahead of the New Year's holiday, and while evidence is building that infections are less severe, the high volume of cases could still stress hospitals, federal health officials said today [Wed 29 Dec 2021] at a White House briefing. In global developments, omicron hot spots drove the global total higher, as new scientific findings had good news about booster doses and the immune response to omicron.

Rochelle Walensky, who directs the Centers for Disease Control and Prevention (CDC), said the 7-day average is at 240 400 cases a day, 60% higher than last week. She added that hospitalizations--which typically lag cases--are averaging 9000 a day, up 14% compared with last week.

In its latest Nowcast estimate, CDC pared back the percentage of omicron cases to 58.6% of sequenced cases, down from 73% last week, reflecting that while omicron is still dominant, especially in some regions, the USA is still feeling the impact from delta.

Five states -- Florida, New York, New Jersey, Massachusetts, and Delaware -- are reporting more new cases than at any other point during the pandemic, according to ABC News. [https://abcnews.go.com/Health/live-updates/coronavirus/?id= 81952698#81972675]

Regarding CDC's recently announced shortened times for isolation and quarantine, Walensky said the updated advice is weighted toward the time when people are most infectious, based on what's currently known. "The virus adapts quickly, and we must adapt with it," she said.

Addressing the issue of why the CDC did not recommend testing in the updated guidance, Walensky said that so far, it's not clear how antigen testing results relate to transmission at day 5 after an initial positive test, and the rapid tests aren't authorized for clearing people from isolation. However, she said masking and staying home when sick are critically important, and the science behind all of the measures were central to the updated recommendations. "They will only work if people follow them," she said of the new guidelines.

Tony Fauci, the White House's chief medical adviser, said data from international research groups and those in the United States hinting at a less severe infection from the omicron variant, though preliminary, are encouraging, with evidence getting stronger and stronger. However, it's not clear if the lower severity is driven by preexisting immunity, intrinsic characteristics of the variant, or both. And due to the sheer volume of cases, hospitals could still feel pressure, he noted.

Regarding rising hospitalizations in children, Fauci said there will naturally be more hospitalizations if infections are surging, but so far, it isn't clear if omicron illnesses are more severe in youngsters. New Year's revelers should only gather with family and friends who are vaccinated and boosted, though there is never a zero risk, Fauci said, adding that people should avoid larger parties, of [say] 40-50 people.

In other US updates, Jeff Zients, White House COVID-19 response coordinator, said about 1 million people are receiving booster shots each day, and nearly 2 of 3 seniors have received their 3rd shots. Regarding the earlier announced plan to provide 500 million rapid tests free of charge in January [2022], he said the government has accelerated the contract timeline to be finalized next week, with the first deliveries to follow. The government will launch a website that will allow Americans to order the rapid tests for free.

In other US developments
------------------------
- The FDA said yesterday [Tue 28 Dec 2021] in an update that early data on antigen tests suggests they do detect the omicron variant but may have reduced sensitivity. [https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests]

- CDC is investigating or monitoring 86 cruise ships with reported COVID-19 cases aboard, according to the Wall Street Journal. [https://www.wsj.com/articles/cdc-investigating-86-cruise-ships-with-covid-19-cases-11640731051]

With the omicron variant fueling a wave of new infections, many colleges and universities around the country have announced that classes will be delayed or begin remotely in January [2022], according to the New York Times. [https://www.nytimes.com/live/2021/12/28/world/omicron-covid-vaccine-tests#many-universities-citing-the-omicron-surge-push-start-dates-back-or-move-to-online-instruction]

- A federal court yesterday [Tue 28 Dec 2021] denied a lawsuit filed by Oklahoma governor Kevin Stitt that challenged the Pentagon's military-wide COVID-19 vaccine mandate, according to the Washington Post. [https://www.washingtonpost.com/nation/2021/12/29/covid-omicron-variant-live-updates/#link-SMWXIQEF7JBSFBTGYKOY6AOWMM]

Global case rise fueled by omicron hot spots
--------------------------------------------
After a few weeks of a plateau pattern, global cases rose last week by 11% compared to the previous week, with the Americas and African regions showing the biggest rises, the World Health Organization (WHO) said yesterday [Tue 28 Dec 2021] in its weekly pandemic update. Meanwhile, deaths held steady. [https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---28-december-2021]

At a WHO briefing today [Wed 29 Dec 2021], director-general Tedros Adhanom Ghebreyesus said omicron and delta are twin threats that are driving up case numbers, along with spikes in hospitalizations and deaths. [https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-press-conference---29-december-2021]. "This is and will continue to put immense pressure on exhausted health workers and health systems on the brink of collapse and again disrupting lives and livelihoods," he said. "The pressure on health systems is not only because of new COVID-19 patients requiring hospitalization but also a large number of health workers are getting sick themselves." He repeated his call for government leaders and industry to follow through on their promises to boost vaccine equity. Though supplies are improving, Tedros warned that the emphasis on boosters in high-income countries could prompt shortages again in low-income countries.

In other global developments
----------------------------
- Several countries saw cases soar to new daily record highs, including Australia. In Europe, France, the United Kingdom, Italy, Greece, Spain, Portugal, and Malta were among the countries reporting record cases.

- A preprint study of about 12 000 households in Denmark suggests a notable drop in omicron transmission in people who had vaccine booster doses compared to households infected with delta. [Lyngse FP, Mortensen LH, Denwood MJ, et al. Omicron VOC transmission in Danish households. medRxiv 2021.12.27.21268278; doi: https://doi.org/10.1101/2021.12.27.21268278]

- In another research development, a team from South Africa reported that most T-cell responses from previous infection or vaccination still recognize the omicron variant. They posted their preprint findings on medRxiv. SARS-CoV-2 [Keeton R, Tincho MB, Ngomti A, et al. SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron. medRxiv 2021.12.26.21268380; doi: https://doi.org/10.1101/2021.12.26.21268380]

[byline: Lisa Schnirring]

--
communicated by:
Mary Marshall

******
[3] Antibody-mediated neutralization of omicron
Date: Wed 29 Dec 2021
Source: Medical Express [edited]
https://medicalxpress.com/news/2021-12-omicron-variant-largely-resistant-current.html


[ref: Hoffmann M, et al, The Omicron variant is highly resistant against antibody-mediated neutralization - implications for control of the COVID-19 pandemic, Cell (2021). DOI: 10.1016/j.cell.2021.12.032]

The spike protein of the SARS-CoV-2 Omicron variant harbors more than 30 mutations compared to the spike of the virus circulating during the early phase of the pandemic. The mutations in the spike protein cause most therapeutic antibodies to be ineffective against the omicron spike and omicron spike evades antibodies produced after infection or homologous (2-shot) BioNTech-Pfizer immunization. Antibodies induced upon triple immunization with BioNTech-Pfizer (= booster) or heterologous vaccination with Oxford-AstraZeneca/ BioNTech-Pfizer inhibited the omicron spike with increased efficiency. Therefore, booster and heterologous vaccination could provide stronger protection against the omicron variant.

The omicron variant of SARS-CoV-2 is spreading at an alarming rate. It could soon replace the delta variant, which at present dominates globally. However, little is known about whether currently available vaccines and drugs will be effective against the omicron variant. To assess the efficiency of vaccines and therapeutic antibodies, a research team led by Stefan Pohlmann and Markus Hoffmann from the German Primate Center--Leibniz Institute for Primate Research in Gottingen and colleagues from the Hannover Medical School, the University of Gottingen Medical Center, the Friedrich-Alexander University of Erlangen-Nurnberg and the German Center for Infection Research in Braunschweig, have studied how efficiently the omicron variant is neutralized by antibodies from recovered and vaccinated people. An inhibition by T cells, which are produced after infection, remains to be analyzed.

The team was able to show that antibodies from recovered persons hardly inhibit the omicron variant. Antibodies after 2 BioNTech-Pfizer vaccinations also showed significantly reduced efficacy against the omicron variant. Better inhibition was observed after triple BioNTech-Pfizer vaccination as well as after heterologous vaccination with Oxford-AstraZeneca and BioNTech-Pfizer. Finally, most of the therapeutic antibodies evaluated in the study were not effective against the omicron variant. These results indicate that several antibodies used to treat COVID-19 will be ineffective against the omicron variant. However, they also suggest that a 3rd immunization with the BioNTech-Pfizer vaccine (booster) and heterologous immunization may protect well against the omicron variant.

Infection with SARS-CoV-2 and vaccination leads to the production of antibodies that strongly contribute to protection against severe disease. In addition, combinations of antibodies produced by biotechnology approaches are being used to treat COVID-19. The spike protein of SARS-CoV-2 facilitates viral entry into cells and constitutes the central target for antibodies that inhibit (neutralize) the virus. Therefore, it is important to determine whether the omicron spike is inhibited by antibodies induced upon vaccination or infection or currently used for COVID-19 treatment. The researchers investigated these questions using non-hazardous virus-like particles that carry the omicron spike and are well suited for analysis of virus entry and its inhibition.

Currently, combinations of the antibodies Casirivimab and Imdevimab, and Etesevimab and Bamlanivimab are used to treat COVID-19. However, the team showed that these antibodies are largely ineffective against the omicron spike. Only one antibody, Sotrovimab, inhibited the omicron spike. "Our cell culture studies suggest that most antibodies currently available for COVID-19 therapy will be ineffective against omicron. Sotrovimab is an exception and could become an important treatment option for omicron-infected patients," concluded Hoffmann.

The researchers further investigated whether patients infected in Germany during the 1st wave of the pandemic had produced antibodies that protect against the omicron variant. While the antibodies inhibited the spike of the virus responsible for the 1st wave, they had little effect against the omicron spike. Therefore, it can be assumed that these individuals do not have robust immune protection against the omicron variant, although an inhibition by T cells, which are also produced during infection, remains to be analyzed.

Antibodies produced after 2 immunizations with the BioNTech-Pfizer vaccine also inhibited the omicron spike significantly less efficiently than the spike proteins of other variants. A better protective effect was observed after 3 immunizations with BioNTech-Pfizer and after heterologous immunization with Oxford-AstraZeneca/BioNTech-Pfizer. These results indicate that dual immunization with BioNTech-Pfizer may protect less efficiently against the omicron variant as compared to the delta variant. In contrast, triple immunization with BioNTech-Pfizer (booster) and cross-vaccination with Oxford-AstraZeneca/BioNTech-Pfizer could establish stronger protection.

--
communicated by:
Mary Marshall
with thanks to @DelthiaRicks

[It still needs to be determined how long the protection that was observed will last. - Mod.LK]

******
[4] Schools
Date: Mon 27 Dec 2021
Source: The Guardian [edited]
https://www.theguardian.com/education/2021/dec/27/staff-shortages-could-force-schools-in-england-to-send-some-pupils-home-omicron


Headteachers say absence caused by spread of omicron variant could undermine government's effort to keep children in schools. Severe staff shortages could undermine the government's efforts to keep pupils in schools, with headteachers in England saying that they may be forced to send some children home if they cannot muster enough staff.

Despite a pledge by [prime minister] Boris Johnson to avoid a repeat of January 2021, when the government insisted schools would remain open only for them to be closed after an abrupt U-turn, school leaders are warning that the rapid spread of the omicron variant could lead to mass absences for teachers and other members of staff when schools reopen for the new year.

Geoff Barton, the general secretary of the Association of School and College Leaders, told the BBC that staff absences had been at "unsustainable" levels at some schools, with up to 25% of staff off in the week leading up to the Christmas break. "We don't know what next week will look like. We're not catastrophising that but we are saying we must have a sense of realism around this," he said.

Paul Whiteman, the general secretary of the National Association of Head Teachers, said it would be "naive" to think omicron would not have an impact on schools when they reopen. "It does seem as though choppy waters lie ahead and that some form of disruption at the start of next term is looking sadly inevitable."

Barton said he "absolutely agrees" with the government's guidance allowing schools to restrict attendance only as a last resort, but argued that school leaders would need to make difficult choices if there were widespread staff absences. "The problem is that if you are running a primary school, and you have got 20 staff and 7 of them can't come in next week, and the pool of supply teachers that you would normally call upon - that is, people have got a relationship with your school and therefore will come and step in at the last minute or a supply agency that will charge you money for doing that at a higher rate - that pool is limited," Barton said.

"You will find yourself in a very difficult position of perhaps trying to teach 2 classes at once in the hall, stuff which will not be good for the quality of education, or you will be in the position of making a decision about whether some year groups should be in school while some aren't." Barton said secondary school leaders could be faced with the dilemma of prioritising classroom teaching for year groups taking exams ahead of teaching for others, "because GCSEs and A-levels really need to go ahead if possible this year".

Last week [w/e 26 Dec 2021] the Department for Education launched a public relations campaign to encourage former teachers in England to sign up with supply agencies, with the education secretary, Nadhim Zahawi, urging people "to come forward if they are available to temporarily fill absences in schools and colleges in the new year."

The Daily Telegraph reported that DfE sources were unable to confirm how many had actually signed up with agencies so far, but that it was "at least hundreds".

[byline: Richard Adams]

--
communicated by:
Mary Marshall

[The US is likely to experience the same dilemma. With the new CDC guidance, teachers and school staff will return to work 5 days after having tested positive for COVID, and without having performed an antigen test showing negative results. They may become unwitting virus spreaders in the school. This will lead to more staff being forced to stay home. Thus, in spite of having the best intentions to maintain a tolerable and functional work/school world, the shortened quarantine time may exacerbate that goal.

There is a lot of disagreement regarding the CDC pronouncement and it is worth reading and considering both sides. - Mod.LK]

******
[5] WHO: Daily new cases reported (as of 29 Dec 2021)
Date: Wed 29 Dec 2021
Source: WHO [abridged, edited]
https://covid19.who.int/table


*Daily case reports as of 29 Dec 2021 16:48 CET

Surveillance
------------
WHO region (no. countries/territories):
Total confirmed cases (new cases in last 24 hours) / Total deaths (new deaths in last 24 hours)
------------------------------------------------------------
Western Pacific Region (19): 11 165 877 (36 542) / 154 667 (298)
European Region (61): 99 133 183 (672 849) / 1 661 105 (4004)
South East Asia Region (10): 44 933 587 (12 940) / 720 545 (334)
Eastern Mediterranean Region (22): 17 122 988 (6495) / 315 400 (97)
Region of the Americas (54): 102 287 397 (568 681) / 2 404 354 (2702)
African Region (49): 7 164 485 (53 668) / 155 675 (170)
Cases on an international conveyance: 764 (0) / 13 (0)

Confirmed cases (new cases in last 24 hours) / Total deaths (new deaths in last 24 hours)
Grand total: 281 808 281 (1 351 175) / 5 411 759 (7605)

--
communicated by:
ProMED

[Data by country, area, or territory for 29 Dec 2021 can be accessed at https://promedmail.org/wp-content/uploads/world-pdf/2021%20WHO%20Daily%20Tables%20DEC29_1640888236.pdf.

- The Americas region reported 42.1% of cases and 35.5% of deaths in the past 24 hours and maintained its position as the most severely affected region, having reported more than 102.28 million cases. The USA reported 525 763 cases followed by Argentina. Another 3 countries reported more than 1000 cases (Brazil, Columbia, Peru, Puerto Rico and Bolivia), in the past 24 hours; and 5 countries reported more than 500 but fewer than 1000 cases (Chile, Ecuador, Dominican Republic, Uruguay, and Panama).

- The European region reported 49.7% of daily case numbers and 52.6% of the daily deaths reported in the past 24 hours, and total cumulative cases reported exceed 99.13 million cases. Some countries not reporting cases in the last 24 hours or longer include Belgium (10 cases), and Tajikistan, among others. A total of 32 countries reported more than 1000 cases in the past 24 hours, with 11 reporting more than 10 000, 21 reporting over 1000 cases, and an additional 3 countries reported more than 500 but fewer than 1000 cases.

- The Eastern Mediterranean region reported 0.48% of daily case numbers and 1.2% of the deaths reported in the past 24 hours, having reported a cumulative total of more than 17.12 million cases. Iran (2128) reported the highest number over the last 24 hours followed by UAE (1846). Saudi Arabia reported more than 500 but fewer than 1000 cases. Jordan, Morocco, Tunisia, Egypt, Libya, and Lebanon among others did not report any cases over the last 24 hours.

- The African region reported 3.9% of daily case numbers and 2.2% of the deaths reported in the past 24 hours, having reported a cumulative total of more than 7.16 million cases. South Africa (7216) reported the highest number over the last 24 hours followed by Ethiopia (7049), Angola (5034), RÃ©union(4807), Mozambique (4146), Zambia (3907), Madagascar (2984), Tanzania (2823), DRC (2444), Zimbabwe (2099), Kenya (1504), Uganda (1272), Ghana (1264), and Cote d'Ivoire (1098), Gabon (1040), and Namibia (1008). Burkina Faso, Malawi, Nigeria, Rwanda and Namibia reported more than 500, but less than 1000 cases over the last 24 hours. A total of 10 countries/territories did not report cases over the last 24 hours.

- The Western Pacific region reported 2.7% of daily case numbers and 3.9% deaths in the past 24 hours, having reported a cumulative total of more than 11.16 million cases. Vietnam (14 440) reported the highest number over the last 24 hours followed by Australia, South Korea, Malaysia, and Lao PDR.

- The South East Asia region reported 0.95% of the daily newly reported cases and 4.3% of reported deaths in the past 24 hours, having reported a cumulative total of more than 44.93 million cases. India is dominant, reporting 9195 cases during the last 24 hours, followed by Thailand (2575). Bangladesh (495), Myanmar (272), Nepal (209), and Indonesia (172), all reported less than 500 cases. Sri Lanka, and Maldives, among others, did not report cases over the last 48 hours.

On the Overview tab at the WHO source URL, the epidemic curve of confirmed COVID-19 cases by WHO region, 30 Dec 2019 through 29 Dec 2021, is an excellent visual representation of the pandemic. - Mod.UBA]

******
[6] Global update: Worldometer accessed 29 Dec 2021 20:23 EST (GMT-5)
Date: Wed 29 Dec 2021
Source: Worldometer [edited]
https://www.worldometers.info/coronavirus/#countries


[For those who wish to see the detailed global data, a snapshot of the Worldometer table at the time we accessed it is available at https://promedmail.org/wp-content/uploads/world-pdf/2021%20WORLDDATA%20DEC29_1640888265.pdf.

A 7-day series of cumulative data reported by countries, territories, and reporting entities can be found at https://promedmail.org/wp-content/uploads/world-pdf/2021%20DEC29WORLD7_1640888300.pdf. Mod.UBA]

Total number of reported deaths: 5 438 627
Total number of worldwide cases: 284 909 138
Number of newly confirmed cases in the past 24 hours: 1 688 309

--
communicated by:
ProMED

[In the past 24 hours, 19 countries -- the USA (508 322), the UK (221 250), France (208 099), Spain (100 760), Italy (98 016), Argentina (42 032), Germany (41 816), Turkey (36 684), Canada (32 017), Greece (28 828), Portugal (26 867), Denmark (22 023), Russia (21 119), Australia (19 662), Switzerland (17 575), Ireland (16 428), Denmark (15 708), Poland (15 567), and Vietnam (13 889) -- all reported over 10 000 newly confirmed cases. A global total of 7587 deaths were reported in the preceding 24 hours (late 28 Dec 2021 to late 29 Dec 2021). The major differences seen over the holiday period will most likely continue over the coming weekend, the rolling 7-day averages are a more precise indicator to follow the trends of the pandemic, while the inflated or under-reported numbers on day to day basis can be misleading.

A total of 68 countries reported more than 1000 cases in the past 24 hours; 48 of the 77 countries are from the European region, 9 are from the Americas region, 5 are from the Western Pacific region, 2 are from the Eastern Mediterranean region, 2 from the South East Asia region, and 11 are from the African region.

Comparing the 7-day averages of daily confirmed cases from the past 7 days and those from 8-14 days ago, case counts have increased by 47.5%, while daily reported deaths have decreased by 3.1%. Similar comparative 7-day averages in the USA show a 76.9% increase in daily reported cases and an 18.6% increase in reported deaths.

Impression: Globally over 1 600 000 newly confirmed infections were reported in the past 24 hours; there are now over 284.90 million cumulative reported cases and over 5.43 million reported deaths. - Mod.UBA]
See Also
COVID-19 update (451): animal, USA, wild deer 20211230.8700589
COVID-19 update (450): maternal Abs, CDC isolation guidance, WHO 20211230.8700575
COVID-19 update (449): global, Israel vacc, pregnancy, future, WHO 20211229.8700554
COVID-19 update (448): France, persistent viral RNA 20211228.8700520
COVID-19 update (447): animal, USA (PA) zoo, lynx 20211227.8700517
COVID-19 update (446): masks, boosters, dysphonia, global 20211226.8700504
COVID-19 update (444): omicron symptoms, mistakes, genetic selection, global 20211225.8700488
COVID-19 update (443): China, masks, quarantine, South Asia, WHO, global 20211224.8700466
COVID-19 update (442): omicron, wastewater, severity, met synd, Paxlovid, WHO 20211224.8700457
COVID-19 update (441): omicron, Germany wastewater detection, rapid tests, WHO 20211222.8700438
COVID-19 update (440): omicron sever., post vacc. graft rejec., Europe, US, WHO 20211222.8700421
COVID-19 update (439): animal, UK (England) zoo, tiger, OIE 20211221.8700411
COVID-19 update (438): UK, Ireland, vaccine certificates, updates global 20211221.8700399
COVID-19 update (437): omicron spread, UK, France, sports teams, global 20211220.8700382
COVID-19 update (436): USA schools, UK hospitals, South Africa, immunity, WHO 20211219.8700372
COVID-19 update (435): PAHO, UK, Europe, omicron impact, South Asia, WHO, global 20211217.8700352
COVID-19 update (434): ECDC risk assessment, Australia, China, boosters, WHO 20211217.8700320
COVID-19 update (433): animal, Colombia (AT) zoo, lion, OIE 20211216.8700315
COVID-19 update (432): omicron spread, modeling, cardiac effects, China, WHO 20211215.8700298
COVID-19 update (431): breakthrough infections, China, Trinidad Tobago, DRC, WHO 20211215.8700273
COVID-19 update (430): animal, USA, Russia, Finland, vaccines 20211214.8700260
COVID-19 update (429): immune escape, travel bans, global 20211213.8700256
COVID-19 update (428): infec in vaccinated, nasal vacc, 3 doses, booster, global 20211212.8700233
COVID-19 update (427): animal, Poland (ZP) mink, OIE 20211212.8700213
COVID-19 update (426): USA, Denmark, rapid saliva test, vaccines, WHO, global 20211212.8700212
COVID-19 update (425): Pfizer booster, AstraZeneca, omicron, Zimbabwe, mortality 20211211.8700188
COVID-19 update (424): cross protec., omicron Kuwait ex Africa, South Korea, WHO 20211209.8700165
COVID-19 update (423): animal, Denmark (SL) zoo, tiger, OIE 20211209.8700158
COVID-19 update (422): omicron, neglected tropical diseases, Uganda, WHO, global 20211208.8700145
COVID-19 update (421): omicron US, PPE issues, South Africa, WHO 20211207.8700131
COVID-19 update (420): animal, Poland (KP) mink, OIE 20211207.8700127
COVID-19 update (410): omicron, WHO update, impact, patience, global 20211130.8699966
COVID-19 update (400): animal, sheep, research, experimental infection 20211121.8699806
COVID-19 update (350): boosters, deaths, cases, vaccines, WHO 20211014.8699041
COVID-19 update (300): Norway, myocarditis, schools, new variant C.1.2, WHO 20210901.8638460
COVID-19 update (200): animal, China, origin 20210608.8433657
COVID-19 update (100): antibodies, vaccine, Thailand, Cambodia, WHO, global 20210316.8250009
COVID-19 update (50): UK vaccine study, Brazil reinfection, WHO 20210205.8167161
COVID-19 update (01): variants, vaccine, Thailand, global, WHO 20210101.80629382020
2020
---
Undiagnosed pediatric inflammatory syndrome (06): COVID-19, heart, young adults 20200522.7364506
COVID-19 update (562): viral load, UK vacc dose, ECDC, WHO 20201231.8061525
COVID-19 update (01): China, global, EVZD, reporting criteria, WHO 20200213.6984084
Novel coronavirus (42): China, global, COVID-19, SARS-CoV-2, WHO 20200211.6979942
Novel coronavirus (01): China (HU) WHO, phylogenetic tree 20200112.6885385
Undiagnosed pneumonia: China (HU) (10): genome available, Hong Kong surveill. 20200111.6883998
Undiagnosed pneumonia: China (01): (HU) wildlife sales, market closed, RFI 20200102.6866757
2019
---
Undiagnosed pneumonia: China (HU): RFI 20191230.6864153
.................................................sb/lk/uba/ao/sh
</body>
